10.1.1. epidemiology, aetiology, pathophysiology diagnosis. ischaemic priapism persistent erection marked rigidity corpora cavernosa little cavernous arterial inflow . ischaemic priapism common subtype priapism, accounting for> 95% episodes . ischaemic priapism, time-dependent metabolic alterations within corpus cavernosum progressively leading hypoxia, hypercapnia, glucopenia acidosis . ischaemic priapism lasts beyond 4 hours similar compartment syndrome characterised development ischaemia within closed space corpora cavernosa, severely compromises cavernosal circulation. emergency medical intervention required minimise irreversible consequences, smooth muscle necrosis, corporal fibrosis development permanent erectile dysfunction (ed) . duration ischaemic priapism represents significant predictor irreversible consequences, thus including ed. context, interventions beyond 48-72 hours onset may help relieve erection pain, little clinical benefit preventing long-term ed . specific pathophysiological causes ischaemic priapism identified cases , although common aetiological factors include sickle cell disease (scd), haematological dyscrasias, neoplastic syndromes, several pharmacological agents (e.g., intracavernosal pge1 therapy) (table 35). ischaemic priapism may occur (0.4-35%) intracavernosal injection erectogenic agents [1336,1340,1344-1346]. risk higher papaverine-based combinations , risk priapism < 1% following prostaglandin e1 injection . second-generation antipsychotics (33.8%), medications (11.3%), alpha-adrenergic antagonists (8.8%) accounted greatest percentage published drug-induced priapism cases . isolated cases priapism described men taken pde5is . data fda adverse reporting system public dashboard showed pde5is-induced priapism accounted 2.9% drug-induced priapism. however, men also risk factors priapism, unclear whether pde5is per se cause ischaemic priapism . since men experience priapism following pde5i treatment additional risk factors ischaemic priapism, pde5is use usually regarded risk factor itself. terms haemoglobinopathies, scd common cause priapism childhood, accounting 63% cases. primary aetiology 23% adult cases . mechanisms scd-associated priapism may involve derangements several signalling pathways penis . contrary traditional belief, maintenance physiological testosterone levels cause priapism, rather preserves penile homeostasis promotes normal erectile function . testosterone deficiency considered controversial risk factor: prevalent patients scd, recent evidence indicates may risk factor priapism . priapism resulting metastatic regional infiltration tumour rare usually reflects infiltrative process, often involving bladder prostate primary cancer sites . large retrospective study including 412 men ischaemic priapism, eleven (3.5%) malignant priapism, seven cases consequence local invasion others secondary haematological malignancy . conventional therapeutic recommendations pharmacological treatment unlikely effective men mri penis offered supportive care medical intervention primary cancer. selected cases palliative treatment options fail control penile pain, palliative penectomy considered. partial priapism, idiopathic partial segmental thrombosis corpus cavemosum, rare condition. often classified subtype priapism limited single crura without ischaemia, rather thrombus present within corpus cavernosum. aetiology unknown, bicycle riding, trauma, drug use, sexual intercourse, haematological diseases α-blocker intake associated partial segmental thrombosis . presence congenital web within corpora also risk factor . table 35: aetiological factors development priapism aetiological factors development priapismidiopathic-haematological dyscrasias, vascular disordersscdthalassemialeukaemiamultiple myelomahaemoglobin olmsted variantfat emboli hyperalimentationhaemodialysisglucose-6-phosphate dehydrogenase deficiencyfactor v leiden mutationvessel vasculitis(e.g., henoch-schönlein purpura; behçet's disease; anti-phospholipid antibodies syndrome)infections (toxin-mediated)scorpion stingspider biterabiesmetabolic disordersamyloidosisfabry’s diseasegoutneurogenic disorderssyphilisspinal cord injurycauda equinasyndromeautonomic neuropathylumbar disc herniationspinal stenosiscerebrovascular accidentbrain tumourspinal anaesthesianeoplasms (metastatic regional infiltration)prostateurethratestisbladderrectallung, kidneymedicationsvasoactive erectile agents (i.e., papaverine, phentolamine, prostaglandin e1/alprostadil, combination intracavernous therapies)α-adrenergic receptor antagonists (i.e., prazosin, terazosin, doxazosin tamsulosin)anti-anxiety agents (hydroxyzine)anticoagulants (heparin warfarin)antidepressants antipsychotics (i.e., trazodone, bupropion, fluoxetine, sertraline, lithium, clozapine, risperidone, olanzapine, chlorpromazine, thioridazine, phenothiazines methylphenidate)antihypertensives (i.e., hydralazine, guanethidine propranolol)hormones (i.e., gonadotropin-releasing hormone testosterone)recreational drugs (i.e., alcohol, marijuana, cocaine [intranasal topical], crack, cocaine) 10.1.1.1. summary evidence epidemiology, aetiology pathophysiology ischaemic priapism summary evidenceleischaemic priapism common type, accounting 95% cases.1bischaemic priapism identified idiopathic patients, sickle cell disease common cause childhood.1bischaemic priapism occurs relatively often (about 5%) intracavernous injections papaverine-based combinations, rare (< 1%) prostaglandin e1 monotherapy.2apriapism rare men taken phosphodiesterase type 5 inhibitors, sporadic cases reported.4